- recruitingPhase III
Astria STAR-0215-302 trial for Navenibart in Hereditary Angioedema
This study looks at a new medicine called navenibart for hereditary angioedema (HAE). It aims to see how safe it is and how well people tolerate it over a long time. Navenibart might help prevent HAE attacks, which can be severe and painful.
United Kingdom · Australia · Austria - active not recruitingPHASE2
A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema
This study is looking into the long-term safety and effects of a treatment called STAR-0215 for people with Hereditary Angioedema (HAE). Participants will receive the treatment for up to five years, helping us understand how it works over a longer period.
United States · Bulgaria · Canada - active not recruitingPHASE3
Berotralstat Treatment in Children With Hereditary Angioedema
This study looks at a medicine called berotralstat for children aged 2 to 11 with hereditary angioedema (HAE). Researchers want to find the right dose for children based on their weight, check if it's safe, and see how well it prevents HAE attacks.
Austria · Canada · France - active not recruitingPHASE3
An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)
This study is looking into the long-term safety of a new medication, KVD900 (Sebetralstat), for teenagers and adults with Hereditary Angioedema (HAE). It is an extension of a previous study, continuing to monitor participants who have already been taking the drug.
United States · Australia · Austria - ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase I, open-label, fixed sequence drug interaction study in healthy subjects to investigate the effect of a 40 mg deucrictibant tablet administered once daily on the pharmacokinetics of the P-gp substrate digoxin and the BCRP substrate rosuvastatin, administered as a drug cocktail
This early-stage study looks at how a new medicine, deucrictibant, affects other common medicines like digoxin and rosuvastatin. It's for healthy volunteers and helps us understand if deucrictibant changes how your body handles these other drugs.
Netherlands - active not recruitingPHASE1, PHASE2
NTLA-2002 in Adults With Hereditary Angioedema (HAE)
This study is testing a new medicine, NTLA-2002, for adults with Hereditary Angioedema (HAE) Type 1 or 2. We want to see if it's safe, how well it works, and how the body handles it. This is an early-stage study.
Australia · France · Germany - active not recruitingPHASE3
HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)
This study is testing a new medicine, NTLA-2002, for people with Hereditary Angioedema (HAE). We want to see how well it works and if it's safe compared to a placebo (a dummy medicine) to reduce HAE attacks.
United States · Australia · Canada - ongoing, recruitingTherapeutic exploratory (Phase II)
ISIS 721744-CS3: An Open-Label Extension Study of ISIS 721744 in Patients with Hereditary Angioedema
This study is looking at a new medicine called ISIS 721744 for people with Hereditary Angioedema (HAE). It's an extension of an earlier study, gathering more information on its safety and how well it helps reduce HAE attacks and improve quality of life.
Netherlands - ongoing, recruitingHuman Pharmacology (Phase I)- Other
An open-label, fixed sequence drug interaction study in healthy subjects to investigate the effect of multiple doses of the gastric acid-reducing agent rabeprazole on the single dose pharmacokinetics of a 40 mg deucrictiban extended-release (XR) tablet.
This study looks at how a new medicine for hereditary angioedema (HAE) interacts with a common stomach acid-reducing drug. It helps us understand if your HAE treatment works differently when you also take medication for heartburn or indigestion.
Germany - enrolling by invitation
Long-Term Follow-Up (LTFU) of Subjects Treated With NTLA 2002
This study is checking on people who previously received a new treatment called NTLA-2002 for hereditary angioedema. It aims to see how they are doing in the long run and understand the lasting effects of the treatment over time.
Australia · France · Germany - recruitingPHASE3
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
This study is looking at a new medicine called ADX-324 for people with Hereditary Angioedema (HAE) Type 1 or 2. It will check if the medicine helps prevent HAE attacks and if it is safe. Researchers will also look at how it affects quality of life.
United States · Argentina · Australia - enrolling by invitationPHASE3
Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies
This study offers ongoing access to a medicine called berotralstat for people with Hereditary Angioedema (HAE) who have already taken part in previous berotralstat studies. It aims to check the long-term safety of the treatment.
Canada · Czechia · France - ongoing, recruitingTherapeutic confirmatory (Phase III)
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema
This study looks at a new medicine called garadacimab for people with hereditary angioedema (HAE). It aims to see if the treatment is safe and helps prevent HAE attacks over a long time. Researchers are checking how many side effects people have and if attacks become less frequent.
Netherlands · Germany · Hungary - ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Crossover Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Attacks in Adolescents and Adults with Hereditary Angioedema.
This study is testing a new soft capsule medicine for people with Hereditary Angioedema (HAE) to quickly stop attacks. It compares the new medicine, called deucrictibant, with a dummy capsule (placebo) and another existing medicine to see how fast it relieves symptoms.
Poland · Germany · Austria - active not recruitingPHASE3
PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial
This study is for young people aged 12-17 with hereditary angioedema (HAE) types 1 or 2 who are already in another KVD900 study. It looks at how the body handles the medicine KVD900 to make sure we understand it better for this age group.
United States · Australia · Austria - active not recruitingPHASE3
A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)
This study looks at a new long-term treatment called donidalorsen for Hereditary Angioedema (HAE). Researchers want to see if it's safe, helps reduce HAE attacks, and improves quality of life for people with this condition over time.
United States · Belgium · Bulgaria - enrolling by invitationPHASE2, PHASE3
Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema
This study looks at a new daily medicine called deucrictibant for people aged 12 and over with hereditary angioedema (HAE). It's for long-term use to treat sudden swelling attacks, including dangerous swelling in the throat. Researchers want to see how safe and effective it is over time.
United States · Argentina · Australia - active not recruitingPHASE4
Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab
This study looks at how safe a medicine called garadacimab is for people aged 12 and over with hereditary angioedema (HAE). It checks if switching to garadacimab from their usual preventative HAE treatment is safe when given once a month for about three months.
United States · Canada · Germany